{"id":192069,"date":"2026-08-10T12:35:29","date_gmt":"2026-08-10T07:05:29","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=192069"},"modified":"2026-08-10T12:35:31","modified_gmt":"2026-08-10T07:05:31","slug":"molbio-diagnostics-initial-public-offering-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/","title":{"rendered":"Molbio Diagnostics IPO 2026: Price, Dates and Business Review"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Molbio Diagnostics IPO opens 10 Aug 2026. Price Rs 768-807. Lot 18 shares, min Rs 14,526. Issue Rs 939.70 Cr. Temasek and MO PE backed. FY26 revenue Rs 1,445 Cr. Listing 17 Aug.<\/em><\/p>\n<p>The Molbio Diagnostics IPO opens for subscription today, 10 August 2026, alongside the Dhoot Transmission issue, making today one of the busiest days of the current primary market calendar. The Molbio Diagnostics IPO is priced at Rs 768 to Rs 807 per share, with a lot size of 18 shares and a minimum retail investment of Rs 14,526 at the upper price band. The issue will remain open until August 12, 2026, with allotment expected on August 13 and shares tentatively scheduled to list on BSE and NSE on August 17, 2026.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=molbio-diagnostics-initial-public-offering-2026\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<p>The Molbio Diagnostics IPO is a Rs 939.70 crore issue comprising a fresh issue of Rs 200 crore and an offer for sale of 91.66 lakh shares worth approximately Rs 739.70 crore. The company is backed by global investor Temasek and Motilal Oswal Private Equity, providing institutional validation for the business. Kotak Mahindra Capital, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors are the book-running lead managers. KFin Technologies is the registrar.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#Molbio_Diagnostics_IPO_Key_Details\" title=\"Molbio Diagnostics IPO: Key Details\">Molbio Diagnostics IPO: Key Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#About_Molbio_Diagnostics_Truenat_and_Point-of-Care_Testing\" title=\"About Molbio Diagnostics: Truenat and Point-of-Care Testing\">About Molbio Diagnostics: Truenat and Point-of-Care Testing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#Molbio_Diagnostics_Financial_Performance\" title=\"Molbio Diagnostics Financial Performance\">Molbio Diagnostics Financial Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#Use_of_Fresh_Issue_Proceeds\" title=\"Use of Fresh Issue Proceeds\">Use of Fresh Issue Proceeds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#Key_Risks\" title=\"Key Risks\">Key Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#What_is_the_Molbio_Diagnostics_IPO_price_band\" title=\"What is the Molbio Diagnostics IPO price band?\">What is the Molbio Diagnostics IPO price band?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#What_is_the_Molbio_Diagnostics_IPO_lot_size\" title=\"What is the Molbio Diagnostics IPO lot size?\">What is the Molbio Diagnostics IPO lot size?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#When_does_the_Molbio_Diagnostics_IPO_close_and_when_will_it_list\" title=\"When does the Molbio Diagnostics IPO close and when will it list?\">When does the Molbio Diagnostics IPO close and when will it list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#What_is_Molbio_Diagnostics_and_what_is_the_Truenat_platform\" title=\"What is Molbio Diagnostics and what is the Truenat platform?\">What is Molbio Diagnostics and what is the Truenat platform?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#Who_are_the_investors_in_Molbio_Diagnostics\" title=\"Who are the investors in Molbio Diagnostics?\">Who are the investors in Molbio Diagnostics?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#What_will_the_fresh_issue_proceeds_be_used_for\" title=\"What will the fresh issue proceeds be used for?\">What will the fresh issue proceeds be used for?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/molbio-diagnostics-initial-public-offering-2026\/#How_do_I_apply_for_the_Molbio_Diagnostics_IPO\" title=\"How do I apply for the Molbio Diagnostics IPO?\">How do I apply for the Molbio Diagnostics IPO?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Molbio_Diagnostics_IPO_Key_Details\"><\/span><strong>Molbio Diagnostics IPO: Key Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #0A0E1A; color: #ffffff;\">\n<th style=\"padding: 9px; border: 1px solid #DDDDDD;\">Particulars<\/th>\n<th style=\"padding: 9px; border: 1px solid #DDDDDD;\">Details<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Issue Size<\/td>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Rs 939.70 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Fresh Issue<\/td>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Rs 200 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Offer for Sale<\/td>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">91.66 lakh shares (~Rs 739.70 crore)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Price Band<\/td>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Rs 768 to Rs 807 per share<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Face Value<\/td>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Re 1 per share<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Lot Size<\/td>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">18 shares (min retail: Rs 14,526)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Open \/ Close<\/td>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">10 August to 12 August 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Allotment<\/td>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">13 August 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Listing<\/td>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">17 August 2026 (NSE and BSE)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Investors<\/td>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Temasek, Motilal Oswal Private Equity<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Lead Managers<\/td>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Kotak, IIFL Capital, Jefferies, Motilal Oswal<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"About_Molbio_Diagnostics_Truenat_and_Point-of-Care_Testing\"><\/span><strong>About Molbio Diagnostics: Truenat and Point-of-Care Testing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Molbio Diagnostics is a Goa-based point-of-care diagnostics company that develops and manufactures diagnostic testing devices and test kits for detecting infectious and other diseases. Its flagship product is the Truenat platform, a portable molecular diagnostic device that delivers results in approximately an hour and has received World Health Organization endorsement for tuberculosis diagnosis. The Molbio Diagnostics IPO offers investors access to a company operating at the intersection of molecular diagnostics, healthcare access and global infectious disease response.<\/p>\n<p>The company&#8217;s manufacturing installed capacity stands at 5,400 devices per annum and 3.9 crore Truenat test kits annually. Molbio Diagnostics has a presence in more than 90 countries, with its customer base spanning government health programmes, hospitals, diagnostic laboratories and international development organisations. The global footprint gives the Molbio Diagnostics IPO a differentiated positioning relative to purely India-focused diagnostics companies.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen Molbio Diagnostics and Healthcare Sector Stocks on Univest<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Molbio_Diagnostics_Financial_Performance\"><\/span><strong>Molbio Diagnostics Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Molbio Diagnostics IPO is supported by strong recent financial growth. Revenue from operations stood at approximately Rs 1,445 crore in FY26, up 41.7 percent from Rs 1,027.94 crore in FY25. Net profit rose 14.8 percent to approximately Rs 164-166 crore in FY26 from Rs 138.58 crore a year earlier. The revenue growth materially outpaced profit growth, suggesting that the company is investing in capacity and capability expansion, which is consistent with the planned use of fresh issue proceeds.<\/p>\n<p>The OFS component of the Molbio Diagnostics IPO (approximately Rs 739.70 crore) is significantly larger than the fresh issue (Rs 200 crore), meaning most of the capital raised will flow to selling shareholders rather than the company itself. Promoter holding will come down from 46.65 percent to 43.01 percent post-issue.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Use_of_Fresh_Issue_Proceeds\"><\/span><strong>Use of Fresh Issue Proceeds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>From the Rs 200 crore fresh issue, the Molbio Diagnostics IPO will deploy Rs 105.5 crore toward establishing a research and development facility, Centre of Excellence and office infrastructure through its wholly owned subsidiary Bigtec. A further Rs 72.2 crore will fund the purchase of plant, machinery and equipment for manufacturing units in Goa and Visakhapatnam. The balance will be used for general corporate purposes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks\"><\/span><strong>Key Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Molbio Diagnostics IPO comes with sector-specific risks. Diagnostics demand can be lumpy, with significant dependence on government procurement decisions and public health programme funding, particularly for infectious disease testing. Competition from global diagnostic majors with larger R&amp;D budgets represents a structural risk to the company&#8217;s long-term pricing power. The company&#8217;s high dependence on the Truenat platform means any technological disruption or competing platform that achieves WHO endorsement could erode its market position. Investors should read the risk factors in the Red Herring Prospectus carefully before applying for the Molbio Diagnostics IPO.<\/p>\n<p>Grey market premium data circulates informally for IPOs but is not published, verified or endorsed by SEBI, NSE or BSE. It is not always accurate and should not be the basis for investment decisions. For GMP updates, readers are advised to check dedicated IPO tracking platforms and verify the information independently.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-ipo\/id1568618904\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.app\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the Molbio Diagnostics IPO subscription, allotment and listing on Univest.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Molbio Diagnostics IPO opens today on 10 August 2026, giving retail investors access to a Goa-based diagnostics company with a WHO-endorsed TB testing platform and a presence in over 90 countries. The Rs 939.70 crore issue is backed by Temasek and Motilal Oswal Private Equity. With FY26 revenue growth of 41.7 percent and a clear plan for using fresh issue proceeds to build R&amp;D and manufacturing capacity, the Molbio Diagnostics IPO presents a differentiated healthcare play in the current IPO market. Always read the RHP and consult a SEBI-registered advisor before investing.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Molbio_Diagnostics_IPO_price_band\"><\/span><strong>What is the Molbio Diagnostics IPO price band?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Molbio Diagnostics IPO price band is Rs 768 to Rs 807 per share with a face value of Re 1 per share.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Molbio_Diagnostics_IPO_lot_size\"><\/span><strong>What is the Molbio Diagnostics IPO lot size?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Molbio Diagnostics IPO lot size is 18 shares. The minimum retail investment is Rs 14,526 at the upper price band of Rs 807. Retail investors can apply for up to 13 lots (234 shares).<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_does_the_Molbio_Diagnostics_IPO_close_and_when_will_it_list\"><\/span><strong>When does the Molbio Diagnostics IPO close and when will it list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Molbio Diagnostics IPO closes on 12 August 2026. Allotment is expected on 13 August 2026. Shares are tentatively scheduled to list on BSE and NSE on 17 August 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Molbio_Diagnostics_and_what_is_the_Truenat_platform\"><\/span><strong>What is Molbio Diagnostics and what is the Truenat platform?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Molbio Diagnostics is a Goa-based point-of-care diagnostics company. Its flagship Truenat platform is a portable molecular diagnostic device endorsed by WHO for tuberculosis diagnosis that delivers results in approximately one hour.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_are_the_investors_in_Molbio_Diagnostics\"><\/span><strong>Who are the investors in Molbio Diagnostics?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Molbio Diagnostics is backed by Temasek, the Singapore-based global investment firm, and Motilal Oswal Private Equity, both of which are existing shareholders participating in the offer for sale component of the Molbio Diagnostics IPO.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_will_the_fresh_issue_proceeds_be_used_for\"><\/span><strong>What will the fresh issue proceeds be used for?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> From the Rs 200 crore fresh issue, Rs 105.5 crore will fund an R&amp;D and Centre of Excellence facility through subsidiary Bigtec, and Rs 72.2 crore will purchase plant and equipment for manufacturing in Goa and Visakhapatnam.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_do_I_apply_for_the_Molbio_Diagnostics_IPO\"><\/span><strong>How do I apply for the Molbio Diagnostics IPO?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> You can apply for the Molbio Diagnostics IPO through the ASBA facility via your bank&#8217;s internet banking platform or UPI-enabled stockbroker apps from 10 August to 12 August 2026.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Molbio Diagnostics IPO opens 10 Aug 2026. Price band Rs 768-807, lot 18 shares, min Rs 14,526. Rs 939.70 Cr issue. Temasek and MO PE backed. Listing 17 Aug.<\/p>\n","protected":false},"author":28,"featured_media":192068,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1281],"tags":[1015],"class_list":["post-192069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","tag-ipo"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["192068"],"_edit_lock":["1786345555:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["1281"],"rank_math_seo_score":["74"],"rank_math_title":["Molbio Diagnostics IPO 2026: Price, Dates and Business Review"],"rank_math_description":["Molbio Diagnostics IPO opens 10 Aug 2026. Price band Rs 768-807, lot 18 shares, min Rs 14,526. Rs 939.70 Cr issue. Temasek and MO PE backed. Listing 17 Aug."],"rank_math_focus_keyword":["Molbio Diagnostics IPO"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["35351"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/molbio-diagnostics-initial-public-offering-2026.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=192069"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192069\/revisions"}],"predecessor-version":[{"id":193375,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192069\/revisions\/193375"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/192068"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=192069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=192069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=192069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}